According to a recent LinkedIn post from SanegeneBio, the company plans to participate in the OPT Congress focused on oligonucleotide, mRNA, and peptide therapeutics in Boston on March 18–19. The post notes that the firm’s CTO and Head of U.S. Operations, Dr. Marc Abrams, intends to present an update on its LEAD™ siRNA delivery platforms and pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post also indicates that Vice President of CMC Development, Dr. Sibo Jiang, is expected to present a case study on siRNA CMC development, emphasizing scalable manufacturing strategies for extrahepatic programs and IND-enabling activities. For investors, this visibility at a specialized industry conference may underscore SanegeneBio’s focus on non-hepatic siRNA applications and manufacturing readiness, potentially supporting its positioning for future partnering, financing, or clinical inflection points in RNA therapeutics.